Liquid biopsy analyzes body fluids for cancer-related markers. Researchers apply this method to track mesothelioma progression. The approach avoids repeated invasive tissue biopsies. Therefore, it offers a safer option for patients.
Mesothelioma often develops in the lining of the lungs or abdomen. Traditional monitoring relies on imaging and tissue samples. However, these methods have limitations. Liquid biopsy detects circulating tumor DNA, circulating tumor cells, and other biomarkers in blood or pleural fluid.
Scientists examine specific genetic changes released by tumor cells. They also study microRNAs and proteins linked to the disease. In addition, advanced sequencing techniques improve detection sensitivity. As a result, doctors gain earlier insights into disease changes.
These approaches help assess treatment response over time. They also reveal signs of residual disease or relapse. Moreover, serial testing allows continuous monitoring without major procedures. Patients experience less discomfort during follow-up care.
Challenges still exist in this field. Low levels of circulating markers can reduce accuracy. Standardization of testing methods remains incomplete. Furthermore, researchers must validate results across larger patient groups.
New technologies continue to strengthen liquid biopsy performance. Multi-marker panels improve reliability. Artificial intelligence tools also support better data interpretation. Consequently, liquid biopsy is becoming a valuable tool in mesothelioma management.
Ongoing studies aim to refine these methods further. They focus on higher sensitivity and clinical usefulness. In the future, liquid biopsy may guide more personalized treatment decisions for mesothelioma patients.